Drugs that contain Cefepime Hydrochloride; Enmetazobactam

1. Exblifep patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7687488 ALLECRA THERAPS 2-substituted methyl penam derivatives
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11124526 ALLECRA THERAPS Crystalline beta-lactamase inhibitor
Nov, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 22, 2029
Generating Antibiotic Incentives Now(GAIN) Feb 22, 2034

NCE-1 date: 22 February, 2033

Market Authorisation Date: 22 February, 2024

Treatment: Use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms;...

Dosage: POWDER

More Information on Dosage

EXBLIFEP family patents

Family Patents